{'fraction_non_alphanumeric': 0.015089163237311385, 'fraction_numerical': 0.0013717421124828531, 'mean_word_length': 5.601809954751131, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Dual Acting Isatin-heterocyclic Hybrids: Recent Highlights as Promising Pharmacological Agents



 For the development of suitable lead molecules to different diseases is a
highly challenging task for medicinal chemists. Nowadays, hybrid pharmacophore concept has
developed as a useful structural modification tool in the drug design of new drug candidates for
different diseases. Hybrid pharmacophore approach consists of combination of two or more pharmacophoric
moieties from different biologically active compounds with complementary functions
or different mechanisms of action into a single molecule. This often results in synergistic activity or
enhanced drug efficacy.



 To develop the suitable leads for different diseases there will be a lot of scope to study
the substitution of heterocyclic moieties on the different positions of isatin ring. The broad and
potent activities of the isatin and their derivatives have been established them as pharmacologically
significant scaffolds. In this review, an attempt has been made with specifically emphasizing the
hybridization of Isatin with different derivatives of heterocyclic compounds on the different positions
of the isatin ring (aryl ring, isatin nitrogen and C2/C3 carbonyl moieties).



 This review highlighted the recent advances of dual acting isatin-heterocyclic hybrids
presenting various pharmacological activities viz., anticancer, antitubercular, anti-inflammatory and
antimicrobial.